UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.725-736

2021

Volltextzugriff (PDF)

Macro-micro dynamic behaviors and fracture modes of roll bonded 7A52/7A01/7B52 aluminum laminates in high velocity deformation

Progress in natural science, 2018-08, Vol.28 (4), p.510-519

2018

Volltextzugriff (PDF)

Prediction of residual stress field on the surface of quenched 7055 aluminium alloy plates

Materials research express, 2022-03, Vol.9 (3), p.36502

2022

Volltextzugriff (PDF)

Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (20), p.7530-7535

2001

Volltextzugriff (PDF)

Structural determinants of the BRCA1 : estrogen receptor interaction

Oncogene, 2005-03, Vol.24 (11), p.1831-1846

2005

Volltextzugriff (PDF)

Biomarker analysis (CTC and ctDNA/RNA) of GT0918 (Proxalutamide) new AR blocker in phase I mCRPC patients with dose escalation

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.186-186

2020

Volltextzugriff (PDF)

Treatment with GT1708F, an Oral Smoothened Inhibitor, in Patients with Myeloid Malignancies: A Phase I Study

Blood, 2023-11, Vol.142 (Supplement 1), p.5964-5964

2023

Volltextzugriff (PDF)

Abstract 711: Repurposing 2nd generation androgen receptor antagonist Proxalutamide to treat COVID-19

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.711-711

2021

Volltextzugriff (PDF)

Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: Preparation, characterization and evaluation in vivo

International journal of pharmaceutics, 2014-11, Vol.475 (1-2), p.97-109

2014

Volltextzugriff (PDF)

High‐resolution structures of inhibitor complexes of human indoleamine 2,3‐dioxygenase 1 in a new crystal form

Acta crystallographica. Section F, Structural biology communications, 2018-11, Vol.74 (11), p.717-724

2018

Volltextzugriff (PDF)

Targeted Protein Degradation for c-MYC Overcomes Therapy Resistance in T-Cell Acute Lymphoblastic Leukemias

Blood, 2023-11, Vol.142 (Supplement 1), p.1447-1447

2023

Volltextzugriff (PDF)

Fe-rich particles influenced secondary crack characteristics in an Al-Zn-Mg-Cu alloy extrusion plate with high zinc content

Scripta materialia, 2020-09, Vol.186, p.259-262

2020

Volltextzugriff (PDF)

Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis

European journal of cancer (1990), 2022-11, Vol.176, p.1-12

2022

Volltextzugriff (PDF)

A partially open conformation of an androgen receptor ligand‐binding domain with drug‐resistance mutations

Acta crystallographica. Section F, Structural biology communications, 2023-04, Vol.79 (4), p.95-104

2023

Volltextzugriff (PDF)

Abstract 1265: Discovery of GT19077, a c-Myc/Max protein-protein Interaction (PPI) small molecule inhibitor, and GT19506 a c-Myc PROTAC molecule, for targeting c-Myc-driven blood cancers and small cell lung cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1265-1265

2021

Volltextzugriff (PDF)

Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1 (ALK-1) antibody, and nivolumab in patients with metastatic hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.326-326

2021

Volltextzugriff (PDF)

Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC

Blood, 2023-11, Vol.142 (Supplement 1), p.583-583

2023

Volltextzugriff (PDF)

Abstract 2735: High affinity and potent anti-tumor efficacy of Nivo813, an anti-PD-1/ALK-1 bispecific antibody, in pre-clinical studies for solid tumors

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.2735-2735

2024

Volltextzugriff (PDF)

Abstract 6509: GT0486, a novel mTORC1/2 dual inhibitor, exhibits synergistic antitumor efficacy in combination with BTK inhibitors

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.6509-6509

2024

Volltextzugriff (PDF)

Abstract 3297: Discovery and evaluation of GT19870, a GSPT1/Myc molecular glue drug (MGD) with oral bioavailability for targeting c-Myc and n-Myc-addictive blood cancer and solid tumors

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.3297-3297

2024

Volltextzugriff (PDF)

A phase Ib study of proxalutamide (GT0918) in women with androgen receptor-positive metastatic breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1019-1019

2021

Volltextzugriff (PDF)

Abstract LB-111: GT19077, a c-Myc/Max protein-protein interaction (PPI) small molecule inhibitor, selectively targets c-Myc-additive B-cell and myeloid malignancies

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.LB-111-LB-111

2020

Volltextzugriff (PDF)

Abstract P2-17-05: Evaluation of safety, pharmacokinetics and pharmacodynamics of proxalutamide (GT0918), a potent androgen receptor (AR) blocker, in patients with metastatic breast cancer (mBC): Phase I dose escalation trial

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P2-P2-17-05

2020

Volltextzugriff (PDF)

A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.108-108

2021

Volltextzugriff (PDF)

Abstract PS15-07: Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PS15-07-PS15-07

2024

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Englisch
(71)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(22)
Technology
(18)
Humans
(13)
Materials Science
(13)
Materials Science, Multidisciplinary
(11)
Animals
(9)
Physical Sciences
(9)
Biochemistry & Molecular Biology
(8)
Oncology
(8)
Engineering
(7)
Chemistry
(6)
Mice
(6)
Binding Sites
(5)
Biological And Medical Sciences
(5)
Chemistry, Physical
(5)
Energy & Fuels
(5)
Female
(5)
Male
(5)
Mutation
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer

Macro-micro dynamic behaviors and fracture modes of roll bonded 7A52/7A01/7B52 aluminum laminates in high velocity deformation

Prediction of residual stress field on the surface of quenched 7055 aluminium alloy plates

Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors

Structural determinants of the BRCA1 : estrogen receptor interaction

Biomarker analysis (CTC and ctDNA/RNA) of GT0918 (Proxalutamide) new AR blocker in phase I mCRPC patients with dose escalation

Treatment with GT1708F, an Oral Smoothened Inhibitor, in Patients with Myeloid Malignancies: A Phase I Study

Abstract 711: Repurposing 2nd generation androgen receptor antagonist Proxalutamide to treat COVID-19

Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: Preparation, characterization and evaluation in vivo

High‐resolution structures of inhibitor complexes of human indoleamine 2,3‐dioxygenase 1 in a new crystal form

Targeted Protein Degradation for c-MYC Overcomes Therapy Resistance in T-Cell Acute Lymphoblastic Leukemias

Fe-rich particles influenced secondary crack characteristics in an Al-Zn-Mg-Cu alloy extrusion plate with high zinc content

Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis

A partially open conformation of an androgen receptor ligand‐binding domain with drug‐resistance mutations

Abstract 1265: Discovery of GT19077, a c-Myc/Max protein-protein Interaction (PPI) small molecule inhibitor, and GT19506 a c-Myc PROTAC molecule, for targeting c-Myc-driven blood cancers and small cell lung cancers

Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1 (ALK-1) antibody, and nivolumab in patients with metastatic hepatocellular carcinoma (HCC)

Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC

Abstract 2735: High affinity and potent anti-tumor efficacy of Nivo813, an anti-PD-1/ALK-1 bispecific antibody, in pre-clinical studies for solid tumors

Abstract 6509: GT0486, a novel mTORC1/2 dual inhibitor, exhibits synergistic antitumor efficacy in combination with BTK inhibitors

Abstract 3297: Discovery and evaluation of GT19870, a GSPT1/Myc molecular glue drug (MGD) with oral bioavailability for targeting c-Myc and n-Myc-addictive blood cancer and solid tumors

A phase Ib study of proxalutamide (GT0918) in women with androgen receptor-positive metastatic breast cancer

Abstract LB-111: GT19077, a c-Myc/Max protein-protein interaction (PPI) small molecule inhibitor, selectively targets c-Myc-additive B-cell and myeloid malignancies

Abstract P2-17-05: Evaluation of safety, pharmacokinetics and pharmacodynamics of proxalutamide (GT0918), a potent androgen receptor (AR) blocker, in patients with metastatic breast cancer (mBC): Phase I dose escalation trial

A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC)

Abstract PS15-07: Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study

Suchergebnisse filtern